Prevention of docosahexaenoic acid-induced cytotoxicity by phosphatidic acid in Jurkat leukemic cells: the role of protein phosphatase-1  by Siddiqui, Rafat A. et al.
Prevention of docosahexaenoic acid-induced cytotoxicity by phosphatidic
acid in Jurkat leukemic cells : the role of protein phosphatase-1
Rafat A. Siddiqui a;*, Laura J. Jenski c, Jacqueline D. Wiesehan a,
Michelle V. Hunter a, Richard J. Kovacs 1;a, William Stillwell b
a Cellular Biochemistry Laboratory, Methodist Research Institute at Clarian Health, 1701 North Senate Boulevard,
Indianapolis, IN 46202, USA
b Department of Biology, Indiana University^Purdue University, Indianapolis, IN, USA
c Department of Biological Sciences, Marshall University, Huntington, WV, USA
Received 8 June 2001; received in revised form 9 August 2001; accepted 30 August 2001
Abstract
The present investigation explores the role of phosphatidic acid (PA), a specific protein phosphatase-1 (PP1) inhibitor, in
cytotoxicity induced by docosahexaenoic acid (DHA). The cytotoxicity of DHA was assayed by quantifying cell survival
using the trypan blue exclusion method. A dose^response effect demonstrated that 5 or 10 WM DHA has no effect on Jurkat
cell survival ; however, 15 WM DHA rapidly decreased cell survival to 40% within 2 h of treatment. Cytotoxicity of 15 WM
DHA was prevented by PA. Structurally similar phospholipids (lysophosphatidic acid, sphingosine 1-phosphate,
sphingosine, and sphingosine phosphocholine) or metabolites of PA (lyso-PA and diacylglycerol) did not prevent DHA-
induced cytotoxicity. PA did not produce micelles alone or in combination with DHA as examined spectrophotometrically,
indicating that PA did not entrap DHA and therefore did not affect the amount of DHA available to the cells. Supporting
this observation, the uptake or incorporation of [1-14C]DHA in Jurkat cells was not affected by the presence of PA. However,
PA treatment reduced the amount of DHA-induced inorganic phosphate released from Jurkat leukemic cells and also
inhibited DHA-induced dephosphorylation of cellular proteins. These observations indicate that PA has exerted its anti-
cytotoxic effects by causing inhibition of protein phosphatase activities. Cytotoxicity of DHA on Jurkat cells was also
blocked by the use of a highly specific caspase-3 inhibitor (N-acetyl-ala-ala-val-ala-leu-leu-pro-ala-val-leu-leu-ala-leu-leu-ala-
pro-asp-glu-val-asp-CHO), indicating that the cytotoxic effects of DHA were due to the induction of apoptosis though
activation of caspase-3. Consistent with these data, proteolytic activation of procaspase-3 was also evident when examined by
immunoblotting. PA prevented procaspase-3 degradation in DHA-treated cells, indicating that PA causes inhibition of
DHA-induced apoptosis in Jurkat leukemic cells. Since DHA-induced apoptosis can be inhibited by PA, we conclude that
the process is mediated through activation of PP1. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Dietary omega-3 fatty acids have long been viewed
as bene¢cial to human health. Over the past few
decades, knowledge of n-3 fatty acids has shifted
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from speculation about their role in maintaining
health to compelling evidence that they are not
only essential for supporting normal physiology,
but may also play a role in preventing and treating
certain diseases [1]. One of the two main n-3 fatty
acids found in ¢sh oil and marine algae, docosahex-
aenoic acid (22:6n-3; DHA) has garnered much of
the attention in recent years. DHA is a signi¢cant
structural component of membrane phospholipids
in tissues throughout the body, particularly in the
retina, brain, and spermatozoa [2,3]. In addition to
developing and maintaining these tissues, DHA has
been shown to inhibit growth of certain cancers. A
1997 epidemiology study of South African West
Coast ¢sherman reported that despite smoking,
high sodium intake, low consumption of ¢ber, fruits,
and vegetables, absence of vitamin supplementation,
and low levels of dietary micronutrients compared to
urban whites, the ¢shermen experienced a lower in-
cidence of colorectal cancer. This was attributed to
the protective e¡ects of ¢sh oils in their diet [4].
Similarly, a population-based case-control epidemiol-
ogy study in Norway demonstrated an inverse rela-
tionship between serum DHA concentrations and
thyroid cancer risk [5]. Various experimental studies
have arrived at similar conclusions. For example,
dietary supplementation with DHA (as a pure fatty
acid or as a component of ¢sh oil) increased apopto-
tic cell death in normal rat colonic cells [6^10], HT-
29 colon cancer cells [11], and the transplantable rat
Morris hepatocarcinoma 3924A [12]; suppressed the
progression of human breast cancer cells, MDA-MB-
231, in athymic nude mice [13,14]; increased survival
time for dogs with lymphoma [15]; reduced risk of
prostate cancer in humans [16]; and signi¢cantly re-
duced the incidence of tumor induction by dimethyl-
benz(a)anthracene in rats [17]. Addition of DHA to
cultures of lung carcinoma A427 [18], Hep2 human
larynx tumor cells [19], pancreatic Mia-Pa-Ca-2 cells
[20], and embryonal carcinoma Tera-2 cells [21] in-
duced apoptosis in these cell lines as well. DHA also
inhibited the growth of cervical cells immortalized by
highly oncogenic human papillomavirus 16 (HPV16),
foreskin keratinocytes immortalized by HPV16, and
keratinocytes grown from papillomas with an HPV
etiology [22]. Furthermore, conjugated DHA with a
triene structure has been shown to induce apoptosis
in DLD-1 cells (colorectal adenocarcinoma) without
any e¡ect on normal human ¢broblast cell lines [23].
From these and many other similar reports, it can be
concluded that DHA can induce apoptosis in various
cells.
Several studies have shown that changes associated
with apoptosis are mediated by activation of protein
phosphatases [24^31]. Wolf and Eastman [27] have
demonstrated that activation of protein phosphatase
1 (PP1) plays an important role in Fas-induced apo-
ptosis by stimulating mitochondrial release of cyto-
chrome c and caspase activation in HL-60 and Jur-
kat cells. Similarly, activation of a PP2A-like
phosphatase has been demonstrated to play a key
role in inducing apoptosis in a neuronal cell line
[26]. Several other studies have shown that cera-
mide-activated protein phosphatase (CAPP), a mem-
ber of the protein phosphatase 2A family, is involved
in receptor-mediated induction of apoptosis in vari-
ous cell lines [28]. These studies suggest that protein
phosphatase activation may be a common feature of
cells undergoing apoptosis. Previous investigation in
our laboratory has shown that DHA-induced apo-
ptosis in Jurkat leukemic cells is mediated by protein
phosphatases, speci¢cally PP1 [31]. Recently, a role
for phosphatidic acid (PA) as a potent and selective
inhibitor of PP1 has been proposed [32]. In this
study, PA prevented ceramide-induced activation of
PP1 in an in vitro system and also prevented ceram-
ide-induced apoptosis in Molt-4 cells [32]. Further-
more, DHA treatment of polymorphonuclear leuko-
cytes has been shown to produce reduced levels of
PA [33]. These observations suggest a regulatory role
for PA in DHA-induced e¡ects, possibly through its
e¡ects on PP1 activities. Therefore, the e¡ects of PA
on DHA-induced apoptosis in Jurkat cells are ex-
plored in the present investigation. Experiments in-
dicate that PA prevents DHA-induced apoptosis
through its e¡ects on protein phosphatase activities.
2. Materials and methods
2.1. Materials
Human Jurkat (clone E6-1) leukemia cells were
obtained from ATCC (American Type Culture Col-
lection, Manassas, VA). Bovine calf serum came
from HyClone Laboratories (Logan, UT) and
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RPMI-1640 was purchased from BioWhittaker (Wal-
kersville, MD). Docosahexaenoic acid, oleic acid
(18:1), linoleic acid (18:2), K-linolenic acid (18:3),
arachidonic acid (20:4), and eicosapentaenoic acid
(20:5) came from Nu-Chek-Prep (Elysian, MN).
Phosphatidic acid, lysophosphatidic acid, sphingo-
sine 1-phosphate, sphingosine, and sphingosine phos-
phocholine were obtained from Avanti Polar Lipids
(Alabaster, AL). Monoclonal anti-procaspase-3
antibody came from Transduction Laboratories
(Lexington, KY). Ethyl alcohol (200 proof) was
obtained from Aldrich (Sheboygen Falls, WI).
[32P]Orthophosphate (8500^9120 Ci/mmol) and
[1-14C]docosahexaenoic acid (40^60 mCi/mmol)
came from NEN (Boston, MA). Tissue Solubilizer
NCS-II was obtained from Amersham Canada (Oak-
ville, ON), and ScintiVerse Scintanalyzed scintillation
£uid was bought from Fisher Scienti¢c (Fairlawn,
NJ). USP iodine came from EM Science (Gibbstown,
NJ). Phosphocellulose ¢lter units were purchased
from Pierce, Rockford, IL. Cell permeable caspase-
3 inhibitor (N-acetyl-ala-ala-val-ala-leu-leu-pro-ala-
val-leu-leu-ala-leu-leu-ala-pro-asp-glu-val-asp-CHO
(DEVD-CHO) was purchased from Biomol Research
Laboratories, Plymouth Meeting, PA. Hank’s Bal-
anced Salt Solution (HBSS), 0.4% trypan blue solu-
tion, ammonium molybdate, ascorbic acid, 6% hy-
drogen peroxide, K2HSO4, concentrated H2SO4,
and all other reagents and chemicals were purchased
from Sigma Chemical Co. (St. Louis, MO).
2.2. Cell culture
Jurkat leukemia cells (clone, E6.1) were cultured
routinely in 2% fetal bovine calf serum in RPMI
1640 supplemented with 100 units/ml of penicillin/
streptomycin and 2 mM glutamine. Cells were incu-
bated in a humidi¢ed atmosphere at 37‡C and 5%
CO2. For experimental purposes, cells were washed
once with serum-free RPMI 1640 supplemented with
100 units/ml of penicillin/streptomycin and 2 mM
glutamine and then suspended into the same media
for treatment with DHA, PA, or other fatty acids, as
indicated. The fatty acids were dissolved in ethanol,
and the ¢nal concentration of ethanol in the culture
medium did not exceed 0.05%. PA and other phos-
pholipids, which were suspended into chloroform,
were dried using N2 and then sonicated in HBSS.
Fatty acids were prepared daily immediately before
use. Control experiments were carried out by adding
ethanol or HBSS to Jurkat cells. Trypan blue exclu-
sion assay, a widely used procedure in apoptosis
studies [34,35], was used to determine cell viability.
2.3. Measurement of [1-14C]DHA incorporation by
thin-layer chromatography (TLC)
Jurkat cells (1U106 cells/ml) were incubated with
15 WM [1-14C]DHA (130 mCi/mol) with or without
PA (25 WM) for 2 h. Cell samples were centrifuged at
4‡C and the supernatants removed. Cells were
washed 3 times with cold phosphate-bu¡ered saline
(PBS), and then phospholipids were extracted using
the method of Bligh and Dyer [36]. Samples sus-
pended in 10^20 Wl of chloroform/methanol (2:1)
were applied to the TLC plate, along with PA, phos-
phatidylserine (PS), phosphatidylcholine (PC), and
phosphatidylethanolamine (PE) standards. The
plates were developed in chloroform/methanol/am-
monium hydroxide (65:25:4). Phospholipids were de-
tected using iodine vapors, and the separated phos-
pholipids were identi¢ed by comparing their
migration on the TLC plate against standard phos-
pholipids. Phospholipid spots were scraped into scin-
tillation vials and counted in a Beckman LS 6500
Multi-Purpose scintillation counter.
2.4. Quantitation of phospholipids
Phospholipids were quanti¢ed as Wmol of phos-
phate per 106 cells, as described previously [37].
Brie£y, the extracted phospholipids (as described
above) or inorganic phosphate standards (0^100
WM) were initially dried under N2 and then digested
in 100 Wl of concentrated H2SO4 at 155‡C for 10
min. After cooling, the digested material was oxi-
dized by adding 50 Wl of 6% hydrogen peroxide.
Samples were vortexed and further heated at 155‡C
for 40 min. Samples were cooled and diluted by add-
ing 2 ml of distilled H2O. Amounts of phosphates
present in the phospholipids or standards were quan-
ti¢ed by adding 800 Wl of a mixture of 10.1 mM
ammonium molybdate/280 mM ascorbic acid (1:1).
The tubes were boiled for 8 min, cooled, and read at
797 nm using a Perkin^Elmer Lambda 40 UV/Vis
spectrometer.
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2.5. Western blotting
After incubation, the cells were treated with 50 Wl
of lysis bu¡er (20 mM Tris^HCl (pH 8.0), 137 mM
NaCl, 100 mM NaF, 2 mM Na3VO4, 10% v/v glyc-
erol, 1% nonylphenyoxy polyethoxy ethanol (Non-
idet P-40), 2 mM phenylmethylsulfonyl £uoride
(PMSF), 1 mg/ml leupeptin, 0.15 units/ml aprotinin,
and 2.5 mM diisopropyl £uorophosphate (DIFP))
for 10 min on ice. Protein concentrations in each
cell lysate were measured using a bicinchoninic acid
(BCA) protein assay system (Pierce). An equal
amount of detergent-solubilized protein extracts
was loaded into a 12% sodium dodecyl sulfate^poly-
acrylamide gel (SDS^PAGE) and separated by elec-
trophoresis. The separated proteins were transferred
electrophoretically onto a polyvinylidene di£uoride
(PVDF) membrane. TTBS (50 mM Tris^HCl (pH
7.4), 150 mM NaCl, 0.05% Tween 20) containing
2% bovine serum albumin (BSA) was used to block
residual binding sites on the membrane. The mem-
branes were then incubated with primary antibody
(anti-procaspase-3, 1:1000 in 1% BSA in TTBS) for
1 h at room temperature. The membranes were then
washed 3 times with TTBS for 10 min each and then
incubated with peroxidase-conjugated antimouse or
antirabbit immunoglobulin G (IgG) (1:1000 dilution
in 1% BSA in TTBS) for 1 h. Blots were developed
using an enhanced-chemiluminescence (ECL) kit and
ECL X-ray ¢lm (Amersham Pharmacia Biotech,
Buckinghamshire, UK).
2.6. Protein phosphatase assays
Protein phosphatase assays were performed both
by measuring the release of inorganic phosphate
into the media and by measuring the amount of
[32P]phosphate incorporated into cellular proteins.
Jurkat cells (3U106/ml) were washed twice with
serum- and phosphate-free RPMI (Gibco Life
Technologies, Rockville, MD) and incubated with
[32P]orthophosphate (100 WCi/ml) for 3 h. Cells
were then washed with serum-free RPMI to remove
unincorporated label. The radiolabeled cells
(1U106/ml) were then incubated with 15 WM
DHA in the presence or absence of 25 WM
DiC10-PA for 2 h. To measure the release of in-
organic phosphate into the media, the incubation
was terminated with chloroform/methanol/HCl
(1:2:0.03), and the samples were partitioned into
aqueous and organic phases, as described [34]. An
aliquot of the aqueous phase (50 Wl) was removed
and counted in a liquid scintillation counter to de-
termine the presence of [32P]phosphate (a measure
of protein phosphatase activities) [24]. Amounts of
inorganic phosphate present in the aqueous phase
of each sample were also determined using a Bio-
mol Green phosphate detection kit (Biomol Re-
search Laboratory, Plymouth Meeting, PA). To
measure the amount of [32P]phosphate incorpo-
rated into cellular proteins, we pelleted cells by
centrifugation at 800Ug for 5 min and lysed the
cells in 50 Wl of lysis bu¡er (as described above).
The insoluble nuclear and membranous material
was removed by centrifugation at 10 000 rpm for
10 min. Twenty micrograms of clear protein extract
was loaded onto a phosphocellulose ¢lter unit
(phosphocellulose inserts in Eppendorf tubes) and
washed 4 times with 75 mM phosphoric acid at
10 000 rpm for 1 min in a microcentrifuge. The
phosphocellulose inserts were then placed in scin-
tillation vials and the amount of radioactivity was
determined by scintillation spectrometry using
Cherenkov counting.
2.7. Lipid peroxidation assay
Lipid peroxidation of DHA in samples was as-
sayed using a lipid peroxidation assay kit (Calbio-
chem^Novobiochem Corp., San Diego, CA) and for-
mation of malondialdehyde (MDA) and 4-
hydroxyalkenals (4-HNE) were measured as per
manufacturer’s protocol. Brie£y, cells after treatment
with DHA (as described above) were lysed by freez-
ing and thawing. The cell homogenate (200 Wl) was
added to 650 Wl of reagent R1 (10.3 mM N-methyl-2-
phenylindole) and mixed with 150 Wl of Reagent R2
(15.4 M methanesulfonic acid). The reaction was in-
cubated at 45‡C for 40 min and then stopped by
cooling on ice. The tubes were centrifuged to remove
cellular debris and the clear supernatant was read at
A586 nm. The amounts of lipid peroxidation products
were quantitated against a set of MDA standards (0^
20 WM). The detection limit for measurable MDA or
4-HNE by this assay was 0.5 WM with a linear rela-
tionship up to 20 WM.
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3. Results
3.1. DHA is cytotoxic to Jurkat cells
The present set of experiments was carried out in
serum-free conditions to determine the cytotoxic
doses of DHA. Analysis of viable cells using the
trypan blue exclusion method, depicted in Fig. 1,
demonstrates that treating Jurkat cells with 5 or 10
WM DHA has very little e¡ect on cell viability,
whereas higher DHA levels induce cytotoxicity.
Only 40% of the cells survived in the presence of
15 WM DHA after 2 h of incubation, whereas almost
all cells died within this period in the presence of 20
WM DHA. Concentrations higher than 20 WM were
extremely toxic, and cells died within 1 h of incuba-
tion (results not shown). In an e¡ort to ¢nd a corre-
lation between the degree of unsaturation (number of
double bonds (dbs)) and the e¡ect on Jurkat cell
viability, we tested 6 di¡erent fatty acids for their
cytotoxic e¡ects. The results shown in Fig. 2a indi-
cate that equal doses of oleic acid (1 db), linoleic acid
(2 dbs), K-linolenic acid (3 dbs), and eicosapentae-
noic acid (5 dbs) are less cytotoxic than DHA. How-
ever, arachidonic acid (4 dbs) decreased Jurkat cell
viability to 60% after 1 h of incubation; this e¡ect
did not change with further incubation up to 2 h.
Results in Fig. 2b demonstrate that a signi¢cant cor-
relation (r = 0.7334, P6 0.001) exists between degree
of unsaturation in fatty acids and cell survival.
Therefore, these results suggest that the DHA e¡ect
is related to its degree of unsaturation.
Fig. 2. E¡ect of fatty acids with various double bonds on Jur-
kat cell viability. Jurkat cells (1U106/ml) were treated with 15
WM of freshly prepared oleic acid (OA), linoleic acid (LOA), li-
nolenic acid (LOEA), arachidonic acid (AA), eicosapentaenoic
acid (EPA), and docosahexaenoic acid (DHA), as described in
the legend of Fig. 1. Controls (CON) were treated with equal
amounts of vehicle (ethanol). After each incubation time, cell
viability was assayed by trypan blue dye exclusion method.
(a) Time course of various fatty acid e¡ects on cell viability.
(b) Relative cell viability after 60 min incubation with various
fatty acids as a function of the number of fatty acid double
bonds. Values are the mean þ S.E.M. (n = 3). Results are ana-
lyzed by Student’s t-test, relative to 0 min incubation:
*P6 0.05, **P6 0.01, ***P6 0.001. Regression analysis was
performed using Sigmaplot (SPSS Science, Chicago, IL).
Fig. 1. E¡ects of docosahexaenoic acid on Jurkat cell viability.
Jurkat cells (1U106/ml) were incubated in the presence of
(b) 0 WM, (a) 5 WM, (S) 10 WM, (P) 15 WM, (F) 20 WM, and
(E) 30 WM concentrations of docosahexaenoic acid for di¡erent
time periods in a 37‡C incubator, as described in the text. After
each incubation time, cell viability was assayed by the trypan
blue dye exclusion method. Values are the mean þ S.E.M.
(n = 3).
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3.2. Speci¢c protein phosphatase-1 inhibitor prevents
DHA-induced cytotoxic e¡ects
We employed phosphatidic acid, a very potent and
highly speci¢c inhibitor of PP1, to explore the role of
PP1 in DHA-induced apoptosis in Jurkat cells. A
dose^response study of PA on cell viability (Fig.
3a) demonstrates that DiC10-PA as low as 10 WM
e¡ectively prevents DHA-induced cell death in Jur-
kat cells. An optimum preventive e¡ect was mea-
sured at 25 WM PA. Furthermore, a time study
Fig. 4. E¡ect of structurally related and bioactive phospholipids
on DHA-induced cytotoxicity. (a) The e¡ects of structurally re-
lated phospholipids were measured by incubating Jurkat cells
(1U106/ml) with either vehicle alone (control), DiC10-PA (PA),
C10-LPA (LPA) (25 WM), sphingosine 1-phosphate (SPP),
sphingosine (S), or sphingosine phosphocholine (SPC) (2.5 WM)
in the absence (black bars) or presence (gray bars) of 15 WM
DHA for 2 h at 37‡C in a humidi¢ed incubator. (b) The e¡ects
of the metabolic products of phosphatidic acid (PA) were mea-
sured by incubating Jurkat cells (1U106/ml) with 25 WM of ei-
ther long-chain (18 carbon) or short-chain (10 carbon) phos-
phatidic acid (PA), lysophosphatidic acid (LPA), or
diacylglycerol (DAG) for 2 h at 37‡C in a humidi¢ed incubator.
Cell viability was assayed by trypan blue dye exclusion method.
Values are the mean þ S.E.M. (n = 3). Results were analyzed by
Student’s t-test, relative to DHA treatment in the absence of
PA: **P6 0.01, ***P6 0.001.
Fig. 3. Dose response and time course of phosphatidic acid on
DHA-induced cytotoxicity on Jurkat cells. For measuring dose^
response e¡ects of PA (a), Jurkat cells (1U106/ml) were incu-
bated for 2 h at 37‡C with various concentrations of PA in the
presence (gray bars) and absence (black bars) of 15 WM DHA.
To measure the time course of PA e¡ects in preventing DHA-
induced cytotoxicity (b), cells (1U106/ml) were incubated with
(b) vehicle alone, (S) 25 WM PA, (a) 15 WM DHA, or (P) 25
WM PA+15 WM DHA at 37‡C for the indicated time periods.
Cell viability was assayed by trypan blue dye exclusion. Values
are the mean þ S.E.M. (n = 3). Results were analyzed by Stu-
dent’s t-test, relative to DHA treatment in the absence of PA:
**P6 0.01, ***P6 0.001.
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(Fig. 3b) demonstrates that the cytotoxic e¡ects of 15
WM DHA leads to complete cell death within 4 to 5 h
of incubation, whereas in the presence of 25 WM PA,
almost 40% of the cells survived after 24 h of incu-
bation with 15 WM DHA. To establish the speci¢city
of PA in preventing DHA-induced cytotoxicity, we
tested lipids structurally related to PA (sphingosine
1-phosphate, lysophosphatidic acid (LPA), sphingo-
sine, and sphingosine phosphocholine). The results
shown in Fig. 4a clearly demonstrate that only PA
was able to provide protection against DHA-induced
cytotoxicity in Jurkat cells. LPA, sphingosine 1-phos-
phate, sphingosine, and sphingosine phosphocholine
did not provide protection; rather, these metabolites
actually enhanced DHA-induced cytotoxicity. We
also tested a few metabolic products of PA to deter-
mine whether the protective e¡ects of PA might be
mediated through its metabolism. The results shown
in Fig. 4b indicate that either long-chain (DiC18:1)
or medium-chain (DiC10) PA was equally e¡ective in
blocking the cytotoxic e¡ects of DHA, whereas nei-
ther diacylglycerol nor LPA was e¡ective.
3.3. PA does not alter uptake or incorporation of
DHA into Jurkat cells
We examined the possibility that PA is forming
micelles that absorb DHA in aqueous solution,
thereby decreasing the availability of DHA to Jurkat
cells, by investigating micelle formation by PA in the
presence and absence of DHA. When suspended in
Hank’s bu¡er in concentrations ranging from 500
nM to 100 WM, PA did not show any visible turbid-
ity (light scattering), as indicated by very low levels
of absorption (0.001^0.01). Furthermore, adding
DHA to PA also did not have any e¡ect on light
absorption (0.002^0.014). The results indicate that
PA does not form micelles alone or in combination
with DHA; therefore, it does not limit DHA’s access
to Jurkat cells (data not shown). To further con¢rm
these results, we next measured the uptake of
[1-14C]DHA by Jurkat cells in the presence or ab-
sence of PA. The results presented in Fig. 5 demon-
C
Fig. 5. E¡ect of PA on uptake of DHA into Jurkat cells. (a)
Jurkat cells (1U106/ml) were incubated with [1-14C]DHA (15
WM; 130 WCi/mol) for various time periods at 37‡C in a hu-
midi¢ed incubator. After each incubation in the absence (b) or
presence (a) of 25 WM PA, cells were washed three times in
cold Ca2- and Mg2-free Hank’s bu¡er and then solubilized in
1 ml of tissue solubilizer (NSC-II). DHA incorporation in Jur-
kat cells was determined by counting the washed cells in a liq-
uid scintillation counter. (b) The percentage incorporation of
DHA in Jurkat cells after 2 h of incubation in the presence and
absence of PA was calculated from the total counts added and
counts recovered in the washed cells. (c) The unincorporated
[1-14C]DHA was determined from radioactivity present in the
supernatant after 2 h of Jurkat cell incubation in the presence
or absence of PA. Values are the mean þ S.E.M. (n = 3). Results
were analyzed by Student’s t-test. NS, not signi¢cant.
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strate uptake of DHA by Jurkat cells. The incorpo-
ration of [1-14C]DHA into Jurkat cells was not sig-
ni¢cantly di¡erent in the presence or absence of PA.
If anything, uptake of DHA in the presence of PA
was relatively higher (but still nonsigni¢cant) than
was observed in the absence of PA (Fig. 5a,b).
Consistent with these results, there was no signi¢-
cant decrease in the amount of unincorporated
[1-14C]DHA found in the supernatants in the pres-
ence of PA (Fig. 5c). Finally, the incorporation of
[1-14C]DHA into the various cell phospholipid
species in the presence or absence of PA was also
measured. Among various phospholipid species,
[1-14C]DHA incorporation was found in the follow-
ing sequence: PCsPEsPSsPA (results not
shown). DHA incorporation into the various phos-
pholipids was not signi¢cantly di¡erent in
the presence or absence of PA (PC = 17 þ 2%
DHA vs. 15 þ 4% DHA+PA; PE = 2 þ 0.3% DHA vs.
2.3 þ 0.5% DHA+PA; PS = 0.6 þ 0.04% DHA vs.
0.8 þ 0.05% DHA+PA; PA = 0.3 þ 0.01% DHA vs.
0.4 þ 0.02 DHA+PA%).
3.4. PA mediates its e¡ects by blocking DHA-induced
activation of protein phosphatases
To con¢rm that PA mediates its e¡ects through
protein phosphatase activities, we incubated Jurkat
cells with 15 WM DHA in the presence or absence
of 25 WM PA. Release of inorganic phosphate was
measured using both radioisotopic and chemical
methods. The results shown in Fig. 6a demonstrate
that DHA caused a signi¢cant release of
[32P]phosphate into the aqueous phase (P6 0.01).
However, in the presence of PA, DHA-induced
[32P]phosphate release decreased to control levels.
In this radioisotopic experiment, it was impossible
to distinguish the radioactivity of free inorganic
phosphate from that of other water-soluble phos-
phate compounds. Therefore, the amount of inor-
ganic phosphates was also measured using a specif-
ic colorimetric assay for free inorganic phosphate.
These results also demonstrated a pattern consis-
tent with the radioisotope assays. Control samples
had about 4 nmol of free phosphate per 106 cells.
With DHA treatment, the amount of phosphate
measured in the aqueous phase was increased to
13 nmol per 106 cells. PA treatment alone caused
the release of phosphate of 9 nmol per 106 cells,
whereas, in cells treated with both DHA and PA
only 3.9 nmol of phosphate per 106 cells were ob-
served in the aqueous phase. Consistent with these
observations, the results shown in Fig. 6b demon-
Fig. 6. Inhibition of DHA-induced protein phosphatase activa-
tion by phosphatidic acid. Cells were labeled with
[32P]orthophosphate, as described in the text. (a) The radiola-
beled cells (1U106/ml) were then incubated with 15 WM DHA
in the presence or absence of 25 WM DiC10-PA for 2 h. Re-
lease of inorganic [32P]phosphate was determined after terminat-
ing the incubation by adding a mixture of chloroform/metha-
nol/HCl (1:2:0.03) and partitioning the samples into aqueous
and organic phases. An aliquot of the aqueous phase (50 Wl)
was removed and counted in a liquid scintillation counter to
determine the presence of [32P]phosphate as a measure of pro-
tein phosphatase activities in each sample. (b) To measure the
amount of [32P]phosphate incorporated into cellular protein,
cell lysates were loaded onto phosphocellulose ¢lter units and
the amount of radioactivity in protein determined, as described
in the text. Values are the mean þ S.E.M. (n = 3). Results were
analyzed by Student’s t-test, relative to control experiment:
**P6 0.01, ***P6 0.001.
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strate that the amount of protein phosphorylation
was signi¢cantly reduced by 50% in the presence of
DHA. While PA alone had no e¡ect on protein
phosphorylation, PA completely abolished the
DHA-induced inhibition of protein phosphoryla-
tion. These results indicate that PA inhibits
DHA-induced activation of protein phosphatases
in Jurkat cells.
3.5. DHA-induced cytotoxic e¡ects are mediated
through apoptosis
To explore the nature of cytotoxic e¡ects of DHA
on Jurkat leukemic cells, we next investigated the
process of apoptosis induction during DHA treat-
ment. As shown in Fig. 7, pretreatment of Jurkat
cells with a highly speci¢c cell-permeable caspase-3
inhibitor (DEVD-CHO) increased cell survival signif-
icantly from 52 þ 5% (DHA-treated) to 83 þ 3%
(DEVD-CHO+DHA-treated) (P6 0.001). These re-
sults indicate that DHA-induced cytotoxicity is medi-
ated through proteolytic activation of caspase-3 and
that prevention of caspase-3 proteolysis by a speci¢c
inhibitor prevents the cytotoxic e¡ects of DHA. The
results shown in Fig. 8 support this observation.
DHA induces procaspase-3 proteolysis such that lev-
els of only 60% of procaspase-3 were measured with-
in 2 h of 15 WM DHA treatment. We further inves-
tigated whether PA prevents DHA-induced apoptosis
by inhibiting procaspase-3 degradation. The results
in Fig. 9 demonstrate that PA alone does not alter
Fig. 9. E¡ect of phosphatidic acid on DHA-induced procas-
pase-3 degradation. Jurkat cells (1U106/ml) were treated with
control vehicle, DHA, PA, or DHA+PA, as described in the
text. After each incubation, cells were lysed and then subjected
to protein separation on a 12.5% SDS^PAGE. The separated
proteins were blotted onto a PVDF membrane. The caspase-3
bands were detected by Western immunoblotting using antipro-
caspase-3 antibodies and were detected by ECL-chemilumines-
cence. Amounts of procaspase-3 were quanti¢ed by densitomet-
ric analysis using KODAK Image Station (440CF) and 1D
image analysis software (Eastman Kodak Co., Rochester, NY).
Values are the mean þ S.E.M. (n = 3). Results were analyzed by
Student’s t-test, relative to DHA treatment: ***P6 0.001.
Fig. 8. Docosahexaenoic acid activates caspase-3 by proteolytic
degradation. Cells (1U106/ml) were grown in the presence or
absence of various concentrations of DHA, as described in the
text. After each incubation, cells were lysed and were then sub-
jected to protein separation on a 12.5% SDS^PAGE. The cas-
pase-3 bands were detected by Western immunoblotting using
anticaspase antibodies (1:1000 dilution in Tris-bu¡ered saline
(pH 8.0) containing 1% fetal calf serum) and were detected by
ECL-chemiluminescence. The blot is a representation of 3 ex-
periments.
Fig. 7. E¡ect of caspase-3 inhibitor on Jurkat cell survival. Jur-
kat cells (1U106/ml) were pretreated with a vehicle (dimethyl
sulfoxide (DMSO) control), or DEVD-CHO, a highly speci¢c
and cell-permeable caspase-3 inhibitor, for 30 min and were
then incubated with 15 WM DHA for 2 h at 37‡C. Cell viability
was assayed by trypan blue dye exclusion. Values are the
mean þ S.E.M. (n = 3). Results were analyzed by Student’s t-test,
relative to DHA treatment: ***P6 0.001.
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the amount of procaspase-3 present in Jurkat cells.
However, DHA-induced degradation of procaspase-3
was prevented by 25 WM PA. These results establish
that PA a¡ects processes upstream of caspase-3 acti-
vation and prevents DHA-induced apoptosis in Jur-
kat leukemic cells.
4. Discussion
In a recent study, we demonstrated that DHA in-
duces apoptosis in Jurkat leukemic cells and that this
process appears to be regulated upstream of caspase-
3 activation by PP1- and PP2B-type protein phos-
phatase activities [31]. In this study, induction of ap-
optosis in Jurkat cells occurred with DHA concen-
trations higher than 30 WM. The high DHA
concentration was required because most of the
DHA in serum is present in bound form [38,39]
and very little may be available as a free fatty acid.
The experiments in the present study were therefore
performed in the absence of serum to determine the
amount of free DHA required to induce cytotoxicity
in Jurkat cells. Furthermore, we tested the role of
PP1 in mediating the cytotoxic e¡ects of DHA by
using phosphatidic acid, a highly speci¢c PP1 inhib-
itor.
The results presented in Fig. 1 demonstrate that
5 WM DHA has almost no e¡ect on Jurkat leukemic
cells. DHA at 10 WM also has no e¡ect on cell via-
bility but appears to arrest growth (unpublished
data). At 15 WM DHA, clear cytotoxic e¡ects could
be observed, while concentrations higher than 20 WM
DHA appear to be extremely toxic to Jurkat cells.
The cytotoxic e¡ect of DHA was clearly related to its
degree of unsaturation (Fig. 2b). These results are
consistent with previously reported data in which a
signi¢cant correlation was found between the num-
ber of fatty acid double bonds and the proportion of
cells undergoing apoptosis in pancreatic and HL-60
cells [20]. Experiments during the present investiga-
tion were performed for shorter incubation times (up
to 2 h), and on each occasion, cells were incubated
with freshly prepared DHA solutions to minimize the
e¡ects of its oxidized products. Our lipid peroxida-
tion assay also did not indicate any signi¢cant lipid
peroxidation (0.6^0.9 WM MDA+4-HNE formed,
which is approximately 4^6% of total (15 WM) added
DHA) in any sample. These results therefore suggest
that DHA, and not its oxidized product(s), was ca-
pable of directly exerting cytotoxic e¡ects in Jurkat
leukemic cells. Alternatively, it is possible that a mo-
lecular species of diacylglycerol (DAG), phosphatidic
acid, or ceramide released from phospholipids con-
taining DHA may be involved [40].
It is of interest to note that DHA exerted anti-
apoptotic e¡ects in neuro 2A cells [41]. This protec-
tive e¡ect of DHA during serum starvation-induced
apoptosis in these cells appears to be mediated by
increased accumulation of DHA in PS fraction in
the neuronal membranes. A time course of DHA
accumulation in di¡erent phospholipid subfractions
was not performed during the current investigation.
However, our previous studies demonstrated a pref-
erential accumulation of DHA in PC and PE frac-
tions in T27A leukemic cells [42]. This discrepancy in
results suggests therefore that di¡erent cell types re-
spond di¡erently to DHA treatment and perhaps the
proapoptotic or antiapoptotic e¡ects of DHA de-
pend on the accumulation of DHA in di¡erent phos-
pholipids in cell membranes.
We then explored the role of PP1 in DHA-induced
cytotoxicity, as suggested by our earlier work [31]. A
recent study has shown that PA selectively inhibits
PP1-mediated e¡ects of ceramide in Molt-4 cells,
while other structurally related lipids, including
LPA and DAG, were without e¡ect [32]. Here we
demonstrate that PA also prevents DHA-induced cy-
totoxicity in Jurkat leukemic cells, while other struc-
turally related lipids, including LPA, SPP, and DAG,
are ine¡ective. Low doses of LPA and SPP have
previously been characterized as antiapoptotic agents
[43,44]. During the present investigation, LPA and
SPP in concentrations ranging from 0.025 WM to
2.5 WM did not prevent DHA-induced cytotoxicity
in Jurkat cells (data not shown). The ability of
LPA and SPP to suppress activation-induced apo-
ptosis of Tsup-1 lymphoblastoma cells was depen-
dent on both cellular expression of the receptors
for lipids and receptors of apoptosis activation sig-
nals [43], whereas inhibition of apoptosis in HL-60
and PC12 cells by SPP depended upon its cellular
uptake [45]. This ¢nding, in agreement with an ear-
lier report [43], indicates that di¡erences exist be-
tween LPA- and SPP-mediated inhibition of apopto-
sis in di¡erent cell types. It is interesting to note that
BBAMCR 14796 7-12-01
R.A. Siddiqui et al. / Biochimica et Biophysica Acta 1541 (2001) 188^200 197
induction of apoptosis in Jurkat leukemic cells is not
mediated through activation of death signal recep-
tors, as no activation of receptor-linked caspase-8
was demonstrated in our earlier study [31]. It is
therefore likely that PA prevents DHA-induced cy-
totoxicity through some other mechanism. Our data
indicate that PA did not simply reduce the availabil-
ity of DHA to Jurkat cells, nor did it reduce DHA
uptake or DHA incorporation into Jurkat cell phos-
pholipids. Furthermore, incorporation of DHA into
phospholipid molecular species was also similar in
the presence or absence of PA. This implies that
PA has a direct e¡ect on DHA-mediated cytotoxic-
ity. Our results demonstrate that DHA treatment of
Jurkat cells causes the activation of protein phospha-
tase and results in enhanced release of inorganic
phosphate into the aqueous phase as measured by
both radiometric and chemical assays. In the experi-
ments presented here, we have also noticed that PA
itself is capable of inducing inorganic phosphate re-
lease in Jurkat cells, probably due to activation of
some other phosphatases. However, results of pro-
tein phosphorylation consistently demonstrate that
signi¢cantly lower amounts of protein were phos-
phorylated in the presence of DHA. While PA is
shown to completely inhibit this e¡ect of DHA, by
itself, PA has no e¡ect on protein phosphorylation.
At this stage, it is not clear how PA causes the en-
hanced inorganic phosphate release. These results in-
dicate that PA inhibits DHA-induced activation of
protein phosphatase, most likely PP1 [28,32]. Inhibi-
tion of PP1 activity by PA then leads to prevention
of DHA-induced cytotoxic e¡ects. In addition to its
e¡ect on PP1 activity, PA is also known for its e¡ects
on several physiological and biochemical processes.
The physiological processes induced by PA include
stimulation of the respiratory burst in neutrophils,
hormone release, platelet aggregation, muscle con-
traction, cell proliferation, and cellular migration
[46]. Intracellular processes that possibly mediate
the biological e¡ects of PA include promotion of
Ca2 entry and mobilization of intracellular calcium;
inhibition of cAMP formation; activation of a num-
ber of enzymes, including protein and lipid kinases,
phospholipases, acyltransferases, and GTPases; stim-
ulation of actin polymerization; and induction of
mRNA for proto-oncogenes and growth factors
[46]. Although some responses to PA depend on its
conversion to diacylglycerol mediated by cellular
ecto-PAPase and the subsequent activation of pro-
tein kinase C [47], this bioactive phospholipid has
long been regarded as a potentially important courier
of extracellular information [48^51]. Because PA has
been shown to potently inhibit PP1 activity in an in
vitro assay system, we propose that exogenous PA is
taken up by Jurkat cells where it exerts its e¡ects by
directly interacting with catalytic or regulatory units
of PP1 [32]. It is also possible that exogenous PA
induces production of intracellular PA [52], which
in turn further inhibits PP1 activation. Furthermore,
Jurkat cells express Edg4, a receptor for LPA, which
also responds to PA as measured in an in vitro re-
porter gene assay system [53]. It is therefore possible
that PA may induce some signaling events (as dis-
cussed above) via activation of the Edg4 receptor
that leads to prevention of DHA-induced cytotoxic-
ity. Clearly, additional experiments are needed to
address the mechanism of PA inhibition of DHA-
induced cytotoxic e¡ects in Jurkat cells. Further-
more, the mechanism of DHA-induced activation
of PP1 is also not known. A recent study has dem-
onstrated that DHA causes reduction of PA levels in
cells [33], which suggests that low cellular levels of
PA may contribute to DHA-induced activation of
PP1.
Our results also indicate that the cytotoxic e¡ects
of 15 WM DHA are due to induction of the apoptotic
process in Jurkat cells, as evidenced by proteolysis of
procaspase-3, and that PA is able to prevent DHA-
induced apoptosis. Activation of PP1 is one of the
regulatory steps in DHA-induced apoptosis in Jurkat
cells [31], and inhibition of this enzyme by PA causes
increased cell survival by inhibiting the apoptotic
process. At present, the identity of the PP1 substrate
that is likely involved in mediating DHA induction
of apoptosis in Jurkat cells is not known. Future
characterization of downstream events of PP1 acti-
vation leading to caspase-3 activation by DHA is
now the focus of our investigation. This will help
to identify the cellular targets of PP1 that mediate
the anticancer e¡ects of DHA.
In conclusion, the present investigation demon-
strates that DHA-induced apoptotic events in Jurkat
leukemic cells can be prevented by phosphatidic acid.
The mechanism appears to involve inhibition of
DHA-induced activation of a PP1 enzyme.
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